ArticleTargeted oncology2020

Correction to: Efficacy and Safety of ABP 798: Results from the JASMINE Trial in Patients with Follicular Lymphoma in Comparison with Rituximab Reference Product.

Dietger Niederwieser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.